Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. Learn how you can help make a difference by joining the All of Us Research Program.
Displaying 61 - 70 of 261
Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)
Biomaterial Product Study
Daily Subcutaneous Metreleptin Treatment in Patients With FPLD
A randomized study to compare Atezolizumab plus Chemotherapy vs HLX10 plus Chemo in ES-SCLC
A Phase 2 Trial of PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Allogenic HCT
Collection of research data and samples from patients who experience immunotherapy side effects
Targeted Treatment for Advanced Non-Small Cell Lung Cancer
This project is being done to assess the effectiveness of adding the drug Cemiplimab to the standard neoadjuvant chemotherapy regimen in patients with estrogen receptor and/or progesterone receptor positive, HER2 negative, or triple-negative invasive breast cancer.
To test if HBI-8000 is a safe and effective addition to the treatment for Melanoma
Preeclamptic Postpartum Antihypertensive Treatment (P-PAT)